Nippon Shinyaku Co., Ltd. (4516.T) Stock

4516.T logo

Nippon Shinyaku Co., Ltd.

4516.TJapan
Healthcare

Company profile

Nippon Shinyaku reported revenue of 160.23 billion JPY for fiscal year 2025, up 8.1% from fiscal year 2024, and net income of 32.56 billion JPY. That is a net profit margin of 20.3% for fiscal year 2025. Its largest business segment, Pharmaceuticals, brought in 87% of segment revenue in fiscal year 2025; Japan was the largest region with 53%. Our analysis of its filings shows revenue growing from 144.18 billion JPY in fiscal year 2023 to 160.23 billion JPY in fiscal year 2025, 5.4% a year on average. Nippon Shinyaku reports about 2,309 full-time employees.

What stands out

  • It spent 34.34 billion JPY on research and development in fiscal year 2025, 21.4% of its revenue.
  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
  • It was founded in 1919.

Figures from company filings; latest fiscal year ended March 31, 2025.

About Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Largest shareholders

  • Meiji Yasuda Life Insurance Co.9.23%
  • Kyoto Financial Group, Inc.4.40%
  • Nippon Shinyaku Co., Ltd.4.06%
  • Mitsubishi Ufj Financial Group, Inc.3.99%
  • Nomura Asset Management Co., Ltd.3.45%

Share of the company, as of September 25, 2026

Leadership

  • Toru Nakai — President & Representative Director, 54
  • Hideyuki Fujii — Accounting & Finance Department Manager
  • Manabu Beppu — Corporate Officer and Head of R & D Planning and Administration Div.
  • Mitsuharu Koizumi — Dir. of HR, Gen. Aff., Risk Man., Compliance, Sustain. & Dig.Tran. and Director, 59
  • Kazuyuki Iwata — GM of Sales and Marketing, Head of Sales & Marketing Division and Director, 59

How much revenue does Nippon Shinyaku make?

Nippon Shinyaku reported 160.23 billion JPY in revenue for fiscal year 2025, up 8.1% from 148.26 billion JPY in fiscal year 2024.

What is Nippon Shinyaku's largest business segment?

Pharmaceuticals, with 138.65 billion JPY or 87% of segment revenue in fiscal year 2025. Next: Functional Food (13%).

Where does Nippon Shinyaku make most of its revenue?

Japan: 53% of revenue by region in fiscal year 2025, followed by Switzerland (33%).

What companies are similar to Nippon Shinyaku?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Kyowa Kirin Co., Ltd. (4151.T), Ono Pharmaceutical Co., Ltd. (4528.T), Sumitomo Pharma Co., Ltd. (4506.T), Sawai Group Holdings Co., Ltd. (4887.T).

How has Nippon Shinyaku's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 121.86 billion JPY; FY2022, 137.48 billion JPY; FY2023, 144.18 billion JPY; FY2024, 148.26 billion JPY; FY2025, 160.23 billion JPY.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees2,309
FoundedSep 23, 1919
IPO DateSep 21, 1962
IPO StatusPublic
HeadquartersKyoto, Japan
FoundersHisomu Ichinose
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
14, Nishinosho-Monguchi-cho, Kyoto, 601-8550
Phone
81 7 5321 1111
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Nippon Shinyaku Co., Ltd. (4516.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4516.T

LinkedInLinkedInXXYouTubeYouTube